Trials / Not Yet Recruiting
Not Yet RecruitingNCT07369986
Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial Cancer
A Phase 2b, Open-Label Study of Iparomlimab and Tuvonralimab to Facilitate Surgery Avoidance in Women With Resectable, Mismatch Repair-Deficient Endometrial Cancer
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Women's Hospital School Of Medicine Zhejiang University · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Efficacy evaluate of iparomlimab and tuvonralimab (a PD-1/CTLA-4 bispecific antibody) in patients with surgically resectable dMMR endometrial cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Iparomlimab and Tuvonralimab (QL1706) | Iparomlimab and Tuvonralimab as a strategy to facilitate non-surgical management in women with surgically completely resectable dMMR endometrial cancer. |
Timeline
- Start date
- 2026-03-01
- Primary completion
- 2027-12-31
- Completion
- 2028-12-31
- First posted
- 2026-01-27
- Last updated
- 2026-01-27
Source: ClinicalTrials.gov record NCT07369986. Inclusion in this directory is not an endorsement.